T1 Definitions & Questions

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/41

encourage image

There's no tags or description

Looks like no tags are added yet.

42 Terms

1
New cards

Intellectual property (IP)

Protection of an invention or discovery.

2
New cards

Invention disclosure

A disclosure to the University of Florida that allows UF to decide whether to file a provisional patent application.

3
New cards

Why disclose an invention?

Without disclosure, research discoveries are rarely commercialized.

4
New cards

Bayh-Dole Act and UF policy

UF employees must disclose intellectual property they create to the Office of Technology Licensing.

5
New cards

UF ownership of intellectual property

UF generally owns intellectual property created by its employees unless it is specifically waived back to the funding agency or inventors.

6
New cards

When does UF have rights to an invention?

When the invention was made while employed at UF and is in the employee's field/discipline, or when it was made using university resources.

7
New cards

Provisional patent application

Provides 12 months before a patent application must be submitted or protection can lapse.

8
New cards

IND

Investigational New Drug application required before initiating clinical trials involving an investigational drug.

9
New cards

Three broad areas of an IND

Animal pharmacology/toxicology studies, manufacturing information, and clinical protocols/investigator information.

10
New cards

Animal pharmacology/toxicology information in an IND

Provides the T0 information supporting the safety of moving the investigational drug into humans.

11
New cards

Clinical protocols/investigator information

Includes detailed protocols for proposed clinical studies to assess whether initial-phase trials will expose subjects to unnecessary risks.

12
New cards

IND 30-day period

After an IND is submitted, the sponsor must wait 30 calendar days before initiating clinical trials so the FDA can review it for safety.

13
New cards

IRB

Institutional Review Board that reviews human research to ensure participants' welfare and rights are protected.

14
New cards

IRB approval requirement

Human research cannot be conducted without prior IRB approval.

15
New cards

Other institutional requirements before Phase I

Informed consent, HIPAA, and blood-borne pathogen training.

16
New cards

Good Clinical Practice (GCP)

Ethical guidelines for designing, recording, and reporting clinical trial results involving human subjects.

17
New cards

Good Manufacturing Practice (GMP)

Guidelines for producing pure, safe, and effective therapeutic agents.

18
New cards

Consequence of violating GCP/GMP

Results may be nullified, requiring the trial to be repeated using the correct procedures before the therapeutic can advance.

19
New cards

Phase I purpose

Establish the maximum-tolerated dose or minimum dose required for full target engagement and define the dose/schedule for Phase II trials.

20
New cards

Phase I secondary endpoints

Optimal route of administration, half-life, bioavailability, target engagement, and therapeutic efficacy if observed.

21
New cards

Phase I therapeutic efficacy

If observed, it is usually not statistically significant because the small sample size makes the study underpowered.

22
New cards

Phase I upside

Provides hope for patients who have exhausted other treatment options.

23
New cards

Phase I downside

Patients experience the highest probability of adverse events with the lowest chance of therapeutic benefit.

24
New cards

Phase I PK

Measures the effects of the body on the drug, including ADME and half-life.

25
New cards

Phase I PD

Measures the effects of the drug on the body, including toxicity, adverse reactions, and maximum-tolerated dose.

26
New cards

Drug half-life

How quickly the drug leaves circulation; helps determine the dosing schedule.

27
New cards

Maximum-tolerated dose (MTD)

The highest dose at which adverse reactions are not observed OR the lowest dose required to fully engage the drug target.

28
New cards

What is the purpose of an invention disclosure?

To allow UF to decide whether to file a provisional patent application and help protect potentially commercializable discoveries.

29
New cards

Why is intellectual property protection important in translational research?

Protecting inventions/discoveries allows them to be developed and potentially commercialized.

30
New cards

What does the Bayh-Dole Act require at UF?

UF employees must disclose intellectual property they create to the Office of Technology Licensing.

31
New cards

How long does a provisional patent application provide before a patent application must be submitted?

12 months.

32
New cards

What is an IND?

An Investigational New Drug application required before initiating clinical trials involving an investigational drug.

33
New cards

What are the three broad areas of an IND?

Animal pharmacology/toxicology studies, manufacturing information, and clinical protocols/investigator information.

34
New cards

Why must a sponsor wait 30 days after submitting an IND?

To give the FDA an opportunity to review the IND for safety and ensure research subjects are not exposed to unreasonable risk.

35
New cards

What must happen before human research can be conducted?

The research must receive prior IRB approval.

36
New cards

What additional institutional requirements are listed before Phase I?

Informed consent, HIPAA, and blood-borne pathogen training.

37
New cards

What is the difference between GCP and GMP?

GCP governs ethical design, recording, and reporting of human clinical trials, while GMP governs production of pure, safe, effective therapeutic agents.

38
New cards

What is the primary endpoint of Phase I?

Establish the MTD or minimum dose required for full target engagement and define the dose/schedule for Phase II.

39
New cards

What are the secondary endpoints of Phase I?

Route of administration, half-life, bioavailability, target engagement, and therapeutic efficacy if observed.

40
New cards

Why is therapeutic efficacy usually not statistically significant in Phase I?

Phase I has a small sample size and is therefore usually underpowered to detect statistically significant efficacy.

41
New cards

What are the major PK measurements in Phase I?

Absorption, distribution, metabolism, excretion, and half-life.

42
New cards

What are the major PD measurements in Phase I?

Toxicity, adverse reactions, and maximum-tolerated dose.